Cationic Copolymer Solid Dispersions for Amorphous Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solid dispersions of hydrophobic active ingredients with cationic copolymers, such as Eudragit E, face challenges in stability and loading capacity, often resulting in active ingredient crystallization at higher loadings, which limits their effectiveness in pharmaceutical applications.
Innovation Solution
A solid dispersion of hydrophobic active ingredients and cationic copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in a weight ratio of 35:65 to 55:45, prepared through processes like spray-drying or melt extrusion, which maintains the active ingredient in an amorphous form and enhances stability and loading capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional cationic copolymers like Eudragit E are used for solid dispersions, then the active ingredient can be embedded in the polymer matrix, but the stability deteriorates and active ingredient crystallization occurs at higher loadings
Solution Approach 1:
The patent changes the compositional parameters of the cationic copolymer by specifying a particular monomer ratio (35:65 to 55:45) of N,N-diethylaminoethyl methacrylate and methyl methacrylate, which optimizes both loading capacity and stability parameters simultaneously
Solution Approach 2:
The patent creates a composite material system by combining the specifically formulated cationic copolymer with hydrophobic active ingredients, where the copolymer matrix provides both high loading capacity and enhanced stability to prevent crystallization
2Quantity of substance
If higher active ingredient loadings are achieved with conventional polymers, then the quantity of active ingredient increases, but active ingredient crystals or large domains are produced
Solution Approach 1:
The patent optimizes the copolymer composition parameters to achieve a balance between loading capacity and homogeneity, allowing high active ingredient content while maintaining molecular dispersion and preventing crystal formation
Solution Approach 2:
The specifically formulated cationic copolymer acts as an intermediary matrix that facilitates high loading capacity while maintaining homogeneity through its optimized monomer composition, preventing phase separation and crystallization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution achieves stable solid solutions with higher active ingredient loadings, preventing crystallization and improving bioavailability, as demonstrated by enhanced release profiles of active ingredients like itraconazole and danazol compared to Eudragit EPO.
Implementation Method 1
maintains the active ingredient in an amorphous form and enhances stability and loading capacity
Implementation Method 2
The use of so-called 'solid dispersions' for improving the solubility and bioavailability of drugs... leads, for example when used in solid pharmaceutical presentation forms of a sparingly soluble active ingredient, to an improved release of the active ingredient
Implementation Method 3
the conversion of the liquid mixture to the solid form is undertaken by spray-drying
Implementation Method 4
The liquid mixture is prepared in a screw extruder with heating and, after extrusion, is solidified by cooling
Data Source
AI summary
Described are solid dispersions of hydrophobic active ingredients and cationic copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in a weight ratio of the monomers of from 35:65 to 55:45. Also described are the preparation and use of such solid dispersions for pharmaceutical dosage forms.